Highly accurate result
in a fully automated system
No need for pre-processing
Self-contained consumable
Results in minutes
Quantify precisely
by electrochemical method
MARK-B™ utilizes MESIA,
a patented technology of BBB inc.
Published Journal Paper
“MESIA: Magnetic force-assisted electrochemical sandwich immunoassays for quantification of prostate-specific antigen in human serum”
- <Analytica Chimica Acta>, March, 2019
_ PhD. Hyundoo Hwang, Leader of BBB R&D Center
Easy.
Quick.
Accurate.
• Deliver lab-quality results
• Connected to anywhere
• Reduces the complexity
• Shorten time to diagnosis
Highly accurate result
in a fully automated system
Once inserted into the instrument, the sample is separated into plasma by our patent technology. In succession, the electrochemical analysis process begins.
No need for pre-processing
Self-contained consumable
Test portfolio
*Not available for sale
Tumor
AFP PSA CEA CA19-9 CA125
Cardiovascular disease
cTnI CK-MB Myoglobin D-dimer
hsCRP NT-proBNP Galectin-3 ST2
Sepsis
PCT IL-6 CRP
Infectious diseases
COVID-19 Influenza A&B
Thyroid
TSH T3 T4
Metabolism
Vitamin D Ferritin
Alzheimer's disease
β-amyloid τ protein NfL
Test portfolio
*Not available for sale
Tumor
AFP PSA CEA CA19-9 CA125
Cardiovascular disease
cTnI CK-MB Myoglobin
D-dimer hsCRP NT-proBNP
Sepsis
PCT IL-6 CRP
Infectious diseases
COVID-19 Influenza A&B
Thyroid
TSH T3 T4
Metabolism
Vitamin D Ferritin
Alzheimer's disease
β-amyloid τ protein NfL
Connectivity!
Cloud server to communicate with MARK-B™ test results
POCT1-A2 protocol, HL7, FHIR® to communicate with DMS
Key specification
**Depends on the analyte
*** Optional